Andreas G Bader
Overview
Explore the profile of Andreas G Bader including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
4991
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morey T, Benatar T, Xu S, Wang L, Ip P, Nitya-Nootan T, et al.
Sci Rep
. 2025 Feb;
15(1):6769.
PMID: 40000726
The T cell antigen coupler (TAC) receptor is a novel synthetic receptor designed to maximize the therapeutic potential of T cells in the absence of tonic signaling or receptor-related toxicities....
2.
Xu S, Wang L, Ip P, Randhawa R, Benatar T, Prosser S, et al.
Cancer Immunol Res
. 2024 Oct;
13(1):35-46.
PMID: 39404622
The T-cell antigen coupler (TAC) is a chimeric receptor that facilitates tumor antigen-specific activation of T cells by co-opting the endogenous T-cell receptor complex in the absence of tonic signaling....
3.
Bezverbnaya K, Hammill J, Cummings D, Bojovic B, Groisman B, Baker C, et al.
Cytotherapy
. 2023 Feb;
25(5):490-501.
PMID: 36781360
B-cell maturation antigen (BCMA) is a clinically validated target for multiple myeloma. T-cell engineered with chimeric antigen receptors (CARs) directed against BCMA have demonstrated robust therapeutic activity in clinical trials,...
4.
Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H, et al.
Br J Cancer
. 2020 Apr;
122(11):1630-1637.
PMID: 32238921
Background: In this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of microRNA-34a (miR-34a), was determined and evaluated...
5.
Zhao J, Guerrero A, Kelnar K, Peltier H, Bader A
Lung Cancer
. 2017 Jun;
108:96-102.
PMID: 28625657
Objectives: EGFR tyrosine kinase inhibitors (TKIs) are widely used to treat NSCLC, primarily patients with activating mutations, with more limited response in wild-type disease. However, even with EGFR-mutated disease, many...
6.
Zhao J, Bader A
Methods Mol Biol
. 2016 Dec;
1517:115-126.
PMID: 27924478
Tumor suppressor miRNAs such as miR-34a inhibit tumor growth by simultaneously regulating the expression of multiple important oncogenes across multiple oncogenic pathways and, therefore, provide a strong rationale for developing...
7.
Beg M, Brenner A, Sachdev J, Borad M, Kang Y, Stoudemire J, et al.
Invest New Drugs
. 2016 Dec;
35(2):180-188.
PMID: 27917453
Purpose Naturally occurring tumor suppressor microRNA-34a (miR-34a) downregulates the expression of >30 oncogenes across multiple oncogenic pathways, as well as genes involved in tumor immune evasion, but is lost or...
8.
Cortez M, Valdecanas D, Niknam S, Peltier H, Diao L, Giri U, et al.
Mol Ther Nucleic Acids
. 2015 Dec;
4:e270.
PMID: 26670277
MiR-34a, an important tumor-suppressing microRNA, is downregulated in several types of cancer; loss of its expression has been linked with unfavorable clinical outcomes in non-small-cell lung cancer (NSCLC), among others....
9.
Cortez M, Ivan C, Valdecanas D, Wang X, Peltier H, Ye Y, et al.
J Natl Cancer Inst
. 2015 Nov;
108(1).
PMID: 26577528
Background: Although clinical studies have shown promise for targeting PD1/PDL1 signaling in non-small cell lung cancer (NSCLC), the regulation of PDL1 expression is poorly understood. Here, we show that PDL1...
10.
Kelnar K, Bader A
Methods Mol Biol
. 2015 Jun;
1317:125-33.
PMID: 26072405
MRX34 has recently entered the clinic as the first therapeutic product based on a microRNA (miRNA) mimic. In order to measure drug concentrations in vivo, a quantitation method is needed...